findmyKOL
Clinical trialNCT01894243CompletedPhase 1Interventional

Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment

SponsorAstraZenecaEnrollment31Solid Tumours
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a 2-part study in patients with advanced solid tumours. Part A will investigate the PK of olaparib in patients with mild or moderate hepatic impairment compared to patients with normal hepatic function; Part B will allow patients with mild or moderate hepatic impairment or normal hepatic function continued access to olaparib after the PK phase and will provide additional safety data.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

12 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Czechia
  • Research Site

    Brno, Czechia

France
  • Research Site

    Bordeaux, France

  • Research Site

    Bordeaux, France

  • Research Site

    Dijon, France

  • Research Site

    Grenoble, France

  • Research Site

    Lyon, France

  • Research Site

    Paris, France

Netherlands
  • Research Site

    Amsterdam, Netherlands

  • Research Site

    Maastricht, Netherlands

South Korea
  • Research Site

    Seoul, South Korea

United Kingdom
  • Research Site

    London, United Kingdom

  • Research Site

    Sutton, United Kingdom

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Olaparib tablet dosing
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
13 Mar 2014
Primary completion
29 Nov 2016
Completion
30 Mar 2017
Last update posted
13 Sept 2019
Registered enrollment
31
Registry id
NCT01894243

Cross-registrations

EU-CTR / CTIS (EudraCT)2013-002246-37
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.